Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 15,616 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin and Connective Tissue Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers

An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients

NCT00734955
View directory record Official record
Conditions
Breast Cancer
Interventions
49-channel optical spectrometer
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 15, 2020 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 3 Interventional Results available

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Doxorubicin, Cyclophosphamide, Docetaxel, Herceptin, Carboplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2014
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2016 · Synced Nov 4, 2026, 4:30 PM EST
Terminated Phase 3 Interventional

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

NCT04869943
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pregabalin in Treating Women With Hot Flashes

NCT00702949
View directory record Official record
Conditions
Breast Cancer, Hot Flashes
Interventions
pregabalin, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
209
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 135 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 4 Interventional

Bilateral Comparison Study of Elidel 1% and Hylatopic Plus Emollient Foam for the Treatment of Subjects With Atopic Dermatitis

NCT01202149
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)
Device
Lead sponsor
Frankel, Amylynne, M.D.
Other
Eligibility
2 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2011 · Synced Nov 4, 2026, 4:30 PM EST
Recruiting Not applicable Interventional

Intraoperative Neuromonitoring (IONM) and Bipolar Electrocautery (BE) During Axillary Lymph Node Dissection (ALND)

NCT07528638
View directory record Official record
Conditions
Breast Cancer, Surgery
Interventions
IONM procedure
Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 4, 2026, 4:30 PM EST
Terminated Phase 2 Interventional

A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer

NCT00607438
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane), Sorafenib (Nexavar)
Drug
Lead sponsor
Veeda Oncology
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2012 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 1Phase 2 Interventional

Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.

NCT00405678
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Training, Chemo only
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 1 Interventional

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

NCT03933943
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
LY3361237, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Anniston, Alabama • Clearwater, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections

NCT00646958
View directory record Official record
Conditions
Infectious Skin Diseases, Bacterial Skin Diseases, Staphylococcal Skin Infections, Streptococcal Infections, Abscess
Interventions
Radezolid, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Montgomery, Alabama • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2014 · Synced Nov 4, 2026, 4:30 PM EST
Completed Not applicable Interventional Results available

Team-Based Connected Health (TCH) to Improve Clinical Outcomes and Access in Atopic Dermatitis

NCT03981926
View directory record Official record
Conditions
Atopic Dermatitis Eczema, Atopic Dermatitis, Eczema
Interventions
Team-Based Connected Health (TCH)
Other
Lead sponsor
University of Southern California
Other
Eligibility
1 Year and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 3 Interventional

Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir

NCT00000985
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Vidarabine, Acyclovir, Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Nov 4, 2026, 4:30 PM EST
Recruiting Phase 1Phase 2 Interventional

NORTHERA (DROXIDOPA) for Dysautonomia in Pediatric Survivors of Menkes Disease

NCT07398508
View directory record Official record
Conditions
Menkes Disease
Interventions
Droxidopa Oral Product, Placebo Control
Drug · Other
Lead sponsor
Stephen G. Kaler
Other
Eligibility
7 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 3 Interventional Results available

A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDs

NCT02706847
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
103
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Nov 4, 2026, 4:30 PM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Biennial CEM in Women With a Personal History of Breast Cancer

NCT06105749
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms, Breast Cancer Female, Neoplasms
Interventions
contrast-enhanced mammography
Device
Lead sponsor
Wendie Berg
Other
Eligibility
30 Years to 79 Years · Female only
Enrollment
1,600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
6
States / cities
Bethel Park, Pennsylvania • Cranberry Township, Pennsylvania • Monroeville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 1 Interventional

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

NCT01791478
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
PI3K inhibitor BYL719, letrozole, laboratory biomarker analysis, pharmacological studies
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 3 Interventional

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

NCT04157985
View directory record Official record
Conditions
Advanced Solid Tumors, NSCLC, Bladder Cancer, HNSCC, Renal Cancer, Melanoma, Anal Cancer, Colorectal Cancer, Cholangiocarcinoma, Gastric Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Cervical Cancer
Interventions
Continue PD-1/PD-L1 Inhibitors treatment, Discontinue PD-1/PD-L1-1 inhibitor
Drug · Other
Lead sponsor
Dan Zandberg
Other
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Nov 4, 2026, 4:30 PM EST
Recruiting Phase 2 Interventional

A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

NCT07737743
View directory record Official record
Conditions
Sjögren's Disease
Interventions
DDY391, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Clearwater, Florida • Tampa, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 4, 2026, 4:30 PM EST
Completed No phase listed Observational

Hunter Outcome Survey (HOS)

NCT03292887
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 1 Interventional

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

NCT01857193
View directory record Official record
Conditions
Breast Cancer
Interventions
ribociclib (LEE011), Exemestane, Everolimus (RAD001)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
8
States / cities
Fayetteville, Arkansas • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Nov 4, 2026, 4:30 PM EST
Completed Not applicable Interventional Results available

Imagio Feasibility Multi-Reader, Multi-Case Study

NCT03708393
View directory record Official record
Conditions
Breast Cancer
Interventions
Imagio (IUS+OA), Imagio Ultrasound, Mammography
Device
Lead sponsor
Seno Medical Instruments Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2021 · Synced Nov 4, 2026, 4:30 PM EST
Recruiting Phase 3 Interventional

Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica

NCT07286214
View directory record Official record
Conditions
Polymyalgia Rheumatica
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
47
States / cities
Avondale, Arizona • Phoenix, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Participants With Actinic Keratoses

NCT02120898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod, Zyclara®, Vehicle Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
27
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Nov 4, 2026, 4:30 PM EST
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer

NCT01632332
View directory record Official record
Conditions
HER2-positive Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
HER-2/neu peptide vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Nov 4, 2026, 4:30 PM EST